Paul Tudor Jones Xenon Pharmaceuticals Inc. Transaction History
Tudor Investment Corp Et Al
- $26.8 Billion
- Q3 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 36,687 shares of XENE stock, worth $1.41 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
36,687
Previous 25,232
45.4%
Holding current value
$1.41 Million
Previous $983,000
46.8%
% of portfolio
0.01%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding XENE
# of Institutions
212Shares Held
70.2MCall Options Held
88.3KPut Options Held
28.8K-
Avoro Capital Advisors LLC New York, NY5.67MShares$217 Million3.36% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.6MShares$176 Million1.77% of portfolio
-
Wellington Management Group LLP Boston, MA3.84MShares$147 Million0.03% of portfolio
-
Braidwell LP Stamford, CT2.71MShares$104 Million3.02% of portfolio
-
Commodore Capital LP New York, NY2.7MShares$103 Million9.03% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.39B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...